Loxo Oncology (LOXO) Releases LOXO-101 Data; Oppenheimer Raises Price Target to $30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Unusual 11 Mid-Day Movers 11/9: (XOMA) (PCL) (STRL) Higher; (RCAP) (FSTR) (EVEP) Lower
November 9, 2015 12:55 PM ESTRCS Capital (NYSE: RCAP) 47.0% LOWER; provided the following update as the Company continues to execute on its plan to rationalize its capital structure, increase financial flexibility and position the Company for long-term growth. As previously noted, the Company's Board of Directors has engaged Lazard Freres & Co. LLC to assist in the exploration of options to raise significant capital and to rationalize the Company's capital structure. As part of this process, the independent directors on the Board, led by Non-Executive Chairman Mark Auerbach, will negotiate and approve any proposals derived... More
Loxo Oncology (LOXO) Issues Encouraging Update on LOXO-101 Phase 1
November 9, 2015 6:17 AM ESTLoxo Oncology (NASDAQ: LOXO) announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Providing a LOXO-101 Phase 1 update, study investigators reported that, as of the October 20, 2015 data cutoff date, 30 patients with solid tumors refractory to standard therapy had been enrolled and treated, including six patients with cancers harboring TRK fusions.... More
